These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34055323)

  • 1. Seeking truer measures of success: Moving toward more rigorous evaluations of industry-led access to medicines programs.
    Ramirez CL; Gajeelee A; Desharnais B; Sherman J; Waters D
    J Glob Health; 2021 May; 11():03062. PubMed ID: 34055323
    [No Abstract]   [Full Text] [Related]  

  • 2. Global "hold-em".
    Cassidy BS
    Geriatr Nurs; 2006; 27(1):21-3. PubMed ID: 16483897
    [No Abstract]   [Full Text] [Related]  

  • 3. Access to medicines report cards.
    Mullard A
    Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895336
    [No Abstract]   [Full Text] [Related]  

  • 4. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

  • 5. Commitment to Impact: Strengthening Measurement of Industry-Led Access-to-Medicines Programs.
    Rockers PC; Reich MR; Kettler H; Wirtz VJ
    Health Syst Reform; 2018; 4(3):188-193. PubMed ID: 30060703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence.
    Rockers PC; Wirtz VJ; Umeh CA; Swamy PM; Laing RO
    Health Aff (Millwood); 2017 Apr; 36(4):706-713. PubMed ID: 28373337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supporting the production of pharmaceuticals in Africa.
    Dong J; Mirza Z
    Bull World Health Organ; 2016 Jan; 94(1):71-2. PubMed ID: 26769999
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing medication access for the uninsured and underinsured.
    Chisholm MA
    Am J Health Syst Pharm; 2005 Aug; 62(16):1653. PubMed ID: 16085926
    [No Abstract]   [Full Text] [Related]  

  • 9. Respecting the right to access to medicines: Implications of the UN Guiding Principles on Business and Human Rights for the pharmaceutical industry.
    Moon S
    Health Hum Rights; 2013 Jun; 15(1):E32-43. PubMed ID: 25006088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADR: a new global phenomenon, thanks to the ICH.
    Prescrire Int; 2013 Apr; 22(137):88. PubMed ID: 23662314
    [No Abstract]   [Full Text] [Related]  

  • 12. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
    Pécoul B
    Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
    [No Abstract]   [Full Text] [Related]  

  • 13. Introduction: Pharmaceutical firms and the right to health.
    de Campos TC; Pogge T
    J Law Med Ethics; 2012; 40(2):183-7. PubMed ID: 22789038
    [No Abstract]   [Full Text] [Related]  

  • 14. Global access to quality-assured medical products: the Oxford Statement and call to action.
    Newton PN; Bond KC;
    Lancet Glob Health; 2019 Dec; 7(12):e1609-e1611. PubMed ID: 31708137
    [No Abstract]   [Full Text] [Related]  

  • 15. Access to medicines is not the business of the pharma industry.
    Brown PJ
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664
    [No Abstract]   [Full Text] [Related]  

  • 16. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MeTA: a welcome force for access to medicines.
    Lancet; 2008 May; 371(9626):1724. PubMed ID: 18502276
    [No Abstract]   [Full Text] [Related]  

  • 19. Can (and should) Africa make its own medicines?
    Kardas-Nelson M
    BMJ; 2015 Apr; 350():h2178. PubMed ID: 25920478
    [No Abstract]   [Full Text] [Related]  

  • 20. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.